COVID-19 response through proposals for infection-control products and telework
First written in FY2020. 3 of 11 entries say "Restated". Latest entry: 2026-03-02.
The whole theme swung hardest in 2026: 2 of 7 companies on the "Worse" side.
32 other companies' latest entry also says "Advanced".
- 2026-03-02AdvancedOther Disclosures
「Based on our Logistics Medium-Term Plan, our Group regards addressing the logistics industry’s increasingly serious “2024 problem,” reducing CO₂ emissions and promoting green procurement as important issues.」
The logistics initiatives specified responses to the 2024 problem, CO₂ emissions reductions and green procurement as concrete measures. - FY2026-H1Continued decline as demand for infection-control products levels offAnnual report
「Infection-control products, including PPE (Note 1), declined 5.2% year on year as demand levelled off」
Demand for infection-control products continued to decline as COVID-19 subsided, and the product group, including PPE, decreased 5.2% year on year. - FY2024Continued decline in demand for infection-control products as COVID-19 subsidesAnnual report
「As COVID-19 subsided, demand for testing-related products and infection-control products declined, down 6.6% and 9.2%, respectively, from the previous fiscal year.」
As COVID-19 subsided, the decline in demand for testing-related products and infection-control products was confirmed for the full fiscal year as well. - FY2024-Q3Continued decline in demand for infection-control products as COVID-19 subsidesAnnual report
「As COVID-19 subsided, demand for testing-related products and infection-control products declined 7.7% and 11.1%, respectively, year on year.」
As COVID-19 subsided, the decline in demand for testing-related products and infection-control products continued through the first 3 quarters, with decreases of 7.7% and 11.1%, respectively, year on year. - FY2024-Q2Decline in demand for infection-control products as COVID-19 subsidesAnnual report
「Sales of surgery-related consumables fell 7.8% year on year, while sales of testing-related products and infection-control products fell 10.9%, as demand for those products declined with the subsiding of COVID-19.」
As COVID-19 subsided, demand for testing-related products and infection-control products declined 7.8% and 10.9%, respectively, year on year. - FY2024-Q1RestatedAnnual report
「Sales increased to ¥1.258 billion, up 1.3% year on year, due to demand for infection-control products remaining at a high level.」
The company states that demand for infection-control products remains at a high level. - FY2023-Q1Continued high demand for infection-control productsAnnual report
「Demand for infection-control products, including PPE (Note 1), also remains high.」
The company states that demand for infection-control products including PPE remains high, separately from its previous disclosures of lower revenue due to the subsiding of price inflation. - FY2022-Q3Revenue declines as price inflation for infection-control products subsidesAnnual report
「Infection-control products, including PPE, for which demand had surged in connection with COVID-19, declined 3.0% year on year as price inflation subsided.」
The company continues to handle infection-control products, but sales declined 3.0% year on year as the impact of higher PPE prices subsided. - FY2022-Q1RestatedAnnual report
「Internal medicine-related products, including diabetes-related products, which the company is addressing as a priority area, increased 13.0% year on year. Infection-control products, including PPE (Note 1), for which demand remained high as a COVID-19 countermeasure, showed substantial growth of 28.8% year on year.」
Demand for infection-control products remained high, and sales of infection-control products including PPE increased 28.8% year on year. The company continues to prioritize its response to infection-control products. - FY2021RestatedAnnual report
「In particular, proposals for infection-control products to healthcare institutions continue to be the highest-priority issue from the perspective of contributing to the healthy longevity of the public, as stated in the group's employee charter. The group has supplied products while responding as far as possible to the differing infection-control product needs of each customer by rapidly sharing the latest infection-protection expertise and information on new product availability within the group.」
The company continues to treat proposals for infection-control products as its highest-priority issue and responds to customer-specific demand by sharing expertise and information on new products within the group. - FY2020First statedAnnual report
「The Group has also taken measures from the perspectives of preventing the spread of infection, supporting medical institutions and care facilities, and ensuring employee safety, including proposing infection-prevention products to medical institutions, refraining from non-essential sales activities, and promoting telework.」
In response to the spread of COVID-19, the company implemented proposals for infection-control products, suspended sales activities, and promoted telework as concrete measures.